Biogen (BIIB) Price Target Lifted to $422 at UBS Despite Caution on Tecfidera Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biogen (BIIB) Weakness Overdone, Buy Pullback: BMO
April 24, 2015 3:32 PM EDTBMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over 6% after the company reported Q1 results that missed consensus. In the view of analyst Jim Birchenough, weakness is overdone and represents a buying opportunity.
"We are reaffirming... More
Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
April 24, 2015 7:01 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $3.82, versus the analyst estimate of $3.88. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.66 billion.
First Quarter 2015 Performance Highlights
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year.TECFIDERA revenues... More